Related Experiment Video
Updated: Mar 1, 2026
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
Development of PARP inhibitors in gynecological malignancies
Yvonne L E Ang1, David S P Tan2
1Department of Hematology-Oncology, National University Cancer Institute, National University Health System, Singapore, Singapore.
Abstract:
PARP inhibitors demonstrate synthetic lethality in tumors with BRCA1/2 mutations and other homologous recombination repair deficiencies by interfering with DNA repair and causing direct toxicity to DNA through PARP trapping. PARP inhibitors have been shown to be beneficial in the treatment of BRCA1/2-mutated ovarian cancers, which has led to a shift in the treatment paradigm of this disease. Further studies to establish the role of PARP inhibitors during earlier stages of treatment are ongoing. The use of PARP inhibitors in other cancers with homologous recombination repair deficiencies, such as breast cancer and prostate cancer, is gradually evolving as well, including their use in the neoadjuvant and adjuvant settings. PARP inhibitor combination strategies with chemotherapy, targeted agents, radiotherapy, and immunotherapy are also being explored. The role of predictive biomarkers, including molecular signatures and homologous recombination deficiency scores based on loss of heterozygosity and other structural genomic aberrations, will be crucial to improved patient stratification to enhance the clinical utility of PARP inhibitors. This may also allow the use of PARP inhibitors to be extended beyond tumors with specific homologous recombination DNA repair gene mutations in the future. An improved understanding of the mechanisms underlying PARP inhibitor resistance will also be important to enable the development of new approaches to increase efficacy. This is a field rich in opportunity, and the coming years should see a better understanding of which patients we should be treating with PARP inhibitors and where these agents should come in over the course of treatment.
Insights
Poly (ADP-ribose) polymerase (PARP) inhibitors show promise in treating BRCA1/2-mutated cancers by targeting DNA repair. Research is expanding their use to earlier treatment stages and other cancers, exploring combinations and biomarkers for better patient selection.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Poly (ADP-ribose) polymerase (PARP) inhibitors leverage synthetic lethality in tumors with BRCA1/2 mutations and homologous recombination repair (HRR) deficiencies.
- PARP inhibitors induce DNA damage and toxicity through PARP trapping, showing efficacy in BRCA1/2-mutated ovarian cancers and shifting treatment paradigms.
Purpose of the Study:
- To review the evolving role and expanding applications of PARP inhibitors in cancer treatment.
- To explore the potential of PARP inhibitors in earlier treatment stages, other cancer types, and combination strategies.
- To highlight the importance of predictive biomarkers and understanding resistance mechanisms for optimizing PARP inhibitor therapy.
Main Methods:
- Review of current clinical applications and ongoing research of PARP inhibitors.
- Analysis of studies investigating PARP inhibitors in various cancer types (ovarian, breast, prostate) and treatment settings (neoadjuvant, adjuvant).
- Exploration of combination therapies (chemotherapy, targeted agents, radiotherapy, immunotherapy) and the role of biomarkers.
Main Results:
- PARP inhibitors are established in BRCA1/2-mutated ovarian cancer, with ongoing trials for earlier treatment stages.
- Expanding use in breast and prostate cancers, including neoadjuvant and adjuvant settings.
- Combination strategies and predictive biomarkers (molecular signatures, HRD scores) are crucial for patient stratification and enhanced efficacy.
Conclusions:
- PARP inhibitors represent a significant advancement in treating HRR-deficient cancers, particularly those with BRCA1/2 mutations.
- Future directions include optimizing treatment timing, expanding to new cancer types, and overcoming resistance through combination therapies and advanced biomarkers.
- Continued research is essential to fully elucidate the optimal use of PARP inhibitors and improve patient outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:34Inhibition of Cdk Activity